USRDS 1999 Point Prevalence Counts by Modality, Data Source, and Year, Count (1000s) Year Center Hemo Functioning Transplant PD Home Hemo Facility Survey (FS) USRDS Database * * Preliminary USRDS/FS 191.9/ / /1.9 III-1

Distribution of Point Prevalent ESRD Patients by Treatment Modality and Year, Year * Preliminary * ESRD Patients (%) Center Hemo Functioning Transplant PD Home Hemo 62.3% 28.1% 8.7% 0.6% III-2 USRDS 1999

Distribution of Point Prevalent Dialysis Patients on December 31 by Year*, *Center Hemodialysis (not shown) = 80-84% ** Preliminary Dialysis Patients (%) Year CAPD CCPD Unspecified Dialysis Home Hemo ** 7.6% 4.4% 0.8% 0.7% III-3 USRDS 1999

Patients on Waiting List for Kidney Transplant and Cadaveric Donor Transplants by Year, Transplants or Patients Awaiting Transplant (1000s) Year On Waiting List Cadaveric Donor Transplants 36,036 8,479 III-4 USRDS 1999

Transplants by Donor Source and Year, * Preliminary Year Transplants (1000s) Cadaveric Living Related Living Unrelated * 8,523 3, III-5 USRDS 1999

Dialysis Modality by Race, 1997 * Race * Preliminary Prevalent Patients (%) Remainder due to Home HD and Uncertain Dialysis III-6 USRDS 1999

Dialysis Modality by Age, 1997* Age * Preliminary Prevalent Patients (%) III-7 Remainder due to Home HD and Uncertain Dialysis USRDS 1999

Delivered Dialysis Dose * for Hemodialysis Patients by Year, Kt/V (Delivered) *Daugirdas corrected Kt/V USRDS Special Study Year(s) **Source: HCFA 1998 ESRD Core Indicators Report; average of 1996 and 1997 INC PREV III-8 USRDS 1999

Year URR (%) Average Urea Reduction Ratio (URR) by Year*, *Source: HCFA 1998 ESRD Core Indicators Report III-9 USRDS 1999

Average Weekly Kt/V Urea*Average Weekly C. Creat.* † Year † (L/week/1.73m 2) * Source: HCFA 1998 ESRD Core Indicators Report Average Weekly Kt/V Urea and Creatinine Clearance for CAPD Patients, by Year, III-10 USRDS 1999

Dialysis Membrane Type Used for Incident HD Patients by Year, Patients with missing membrane type are excluded. USRDS Special Study Year(s) III-11 CMAS DMMS W-1 DMMS W-2 Synthetic Cellulose Modified Cellulose HF LF Incident HD Patients (%) USRDS HF

Membrane Type* by Census Region, Census Region * On about day 60 of ESRD from DMMS Wave 2 Incident HD Patients (%) III USRDS 1999

Hematocrit in Hemodialysis Patients, Average Hematocrit (Vol. %) Prevalent on EPO *HCFA 1998 ESRD Core Indicators Report Year III-13 All Prevalent at Year End* All Incident (Medical Evidence Form) USRDS 1999